Intarcia’s diabetes drug-device combo voted down again by FDA panel
The 19-member advisory committee unanimously voted against Intarcia in the review, citing cardiovascular and kidney safety concerns.
Intarcia’s diabetes drug-device combo voted down again by FDA panel Read More »
